Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03958643|
Recruitment Status : Completed
First Posted : May 22, 2019
Last Update Posted : May 31, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Sickle cell disease is a common inherited blood disorder. Kidney disease is a major cause of problems in people with sickle cell disease. In order to identify kidney problems early and stop the progression of kidney disease, doctors need the most accurate tests to check kidney function. Researchers hope to understand more about how to test for kidney disease in people with sickle cell disease.
To determine which of two different lab tests is the best to measure kidney function in adults with sickle cell disease.
People 18 years and older who have sickle cell disease
Participants will be screened with a medical history and blood tests.
Participants will have up to 3 visits.
Participants will collect their urine in a special container over 24 hours.
At the first visit, participants will have blood tests. They will bring their container of urine to the visit. They will have an iothalamate test. For the test, they will get a catheter: a small tube will be inserted into a vein. A special contract agent will be injected into the vein. Blood will be collected over the next 4 hours to test kidney function.
Participants will return the next day for a second visit. They will have blood tests. They will have an MRI. For the MRI, they will like on a table that slides into a machine that takes pictures of the kidneys. They may have the MRI in a third visit.
|Condition or disease|
|Sickle Cell Disease|
The characteristic sickling of red blood cells in hypoxic conditions is the root cause of pathology in sickle cell disease (SCD). When this sickling occurs in the renal microvasculature, and is compounded by chronic vasculopathy related to hemolysis, the result is local infarction, ischemic injury, and interstitial fibrosis. The kidney damage begins in early childhood and is cumulative over time, resulting in sickle cell nephropathy (SCN). Creatinine clearance remains the most commonly used method to evaluate renal function in SCD patients although serum creatinine generally over-estimates the GFR in SCD. Cystatin-C (Cys-C) is freely filtered. Unlike creatinine, it is not secreted by the tubules. Its serum levels correlate with GFR in adults with various kidney diseases as well as in pediatric and adult SCD populations as compared with creatinine-based assessments.
This study seeks to evaluate whether Cys-C is a better noninvasive measure of renal function in the adult sickle cell population than creatinine. Further, this work will elucidate the ability of other markers, including beta 2-microglobulin (beta 2M) and endothelin-1 (ET-1), to predict sickle nephropathy. Finally, renal imaging by MRI will be performed and correlated with measured GFR and renal function markers. The results of this study could help alter clinical practice and thereby ensure the most accurate non-invasive assessment of kidney function by substantiating the role of Cys-C, beta 2M and ET-1 in adults with SCD. Finally, the descriptive analysis including measured GFR with renal MRI, novel biomarkers, markers of hemolysis, and analysis of urinary protein secretion will contribute to a better understanding of the pathophysiology of SCN.
|Study Type :||Observational|
|Actual Enrollment :||70 participants|
|Official Title:||Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy|
|Actual Study Start Date :||May 24, 2019|
|Actual Primary Completion Date :||May 1, 2021|
|Actual Study Completion Date :||February 8, 2022|
In a population of adult patients with SCD we will comprehensively evaluate renal function.
- Determine whether serum cystatin C or serum creatinine-based GFR methods better estimate renal function in the adult sickle cell population [ Time Frame: 2 years ]In a population of patients with sickle cell anemia (including HbSS, HbS-0 thalassemia), who are age 18 and above, we will comprehensively evaluate renal function with the following primary objective:-determine whether serum cystatin C or serum creatinine- based GFR methods better estimate renal function in the adult sickle cell population
- Determine whether endothelin-1 or beta-2 microglobulin correlates with measured GFR (mGFR) [ Time Frame: 2 years ]Determine whether endothelin-1 or beta-2 microglobulin correlates with measured GFR (mGFR)-establish potential correlation between mGFR, endothelin-1, or beta-2 microglobulin and renal blood flow-characterize the proteinuria associated with sickle cell disease-characterize kidney anatomy in patients with sickle cell disease-ascertain if markers of hemolysis are associated with mGFR or renal iron deposition-quantify renal iron burden in sickle cell disease
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- INCLUSION CRITERIA:
Known diagnosis of Sickle Cell Anemia (Hb SS or HbS-beta0-thal) >=18 years of age
Willingness and capacity to provide written informed consent
Uncontrolled/poorly controlled hypertension
GFR <30 ml/min/1.73m2
Uncontrolled infection or acute illness
Chronic inflammatory disease (e.g. lupus, multiple sclerosis, rheumatoid arthritis)
Allergy to iodine or iodinated contrast solutions
Hydroxyurea initiation or dose adjustment <2mo prior
Initiation of chronic transfusion therapy <2mo prior
Antihypertensive medication initiation or dose adjustment <1mo prior
Pain crisis in preceding 4weeks
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03958643
|United States, Maryland|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Emily M Limerick, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|
Documents provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):
|Responsible Party:||National Heart, Lung, and Blood Institute (NHLBI)|
|Other Study ID Numbers:||
|First Posted:||May 22, 2019 Key Record Dates|
|Last Update Posted:||May 31, 2023|
|Last Verified:||May 26, 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Anemia, Sickle Cell
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Male Urogenital Diseases
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn